



**BlueCross
BlueShield**

Federal Employee Program.

XURIDEN (uridine triacetate)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Xuriden is used to treat hereditary orotic aciduria, an extremely rare genetic disorder where the body cannot make uridine due to a deficient enzyme. Uridine is a critical component of ribonucleic acid (RNA), which plays a vital role in countless cell functions. The disease generally manifests itself as blood abnormalities, urinary tract obstruction (due to formation of orotic acid crystals in the urinary tract), failure to thrive, and developmental delays. Xuriden works by replacing uridine so that RNA can continue with its necessary function (1).

Regulatory Status

FDA-approved indication: Xuriden is a pyrimidine analog for uridine replacement indicated for the treatment of hereditary orotic aciduria (1).

Summary

Xuriden is a pyrimidine analog indicated for hereditary orotic aciduria. Hereditary orotic aciduria is a rare genetic disorder. The safety and effectiveness of Xuriden have been established in pediatric patients with hereditary orotic aciduria (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Xuriden while maintaining optimal therapeutic outcomes.

References

1. Xuriden [package insert]. West Conshohocken, PA:BTG International Inc.; August 2023.